|
US4405616A
(en)
|
1975-06-19 |
1983-09-20 |
Nelson Research & Development Company |
Penetration enhancers for transdermal drug delivery of systemic agents
|
|
US3989816A
(en)
|
1975-06-19 |
1976-11-02 |
Nelson Research & Development Company |
Vehicle composition containing 1-substituted azacycloheptan-2-ones
|
|
US4316893A
(en)
*
|
1975-06-19 |
1982-02-23 |
Nelson Research & Development Co. |
Vehicle composition containing 1-substituted azacycloalkan-2-ones
|
|
US4557934A
(en)
|
1983-06-21 |
1985-12-10 |
The Procter & Gamble Company |
Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
|
|
US4524008A
(en)
|
1983-12-16 |
1985-06-18 |
E. I. Du Pont De Nemours And Company |
Controlled initiation chromium dioxide synthesis
|
|
US4568343A
(en)
|
1984-10-09 |
1986-02-04 |
Alza Corporation |
Skin permeation enhancer compositions
|
|
US5023252A
(en)
*
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US4783450A
(en)
|
1987-04-13 |
1988-11-08 |
Warner-Lambert Company |
Use of commercial lecithin as skin penetration enhancer
|
|
US4992445A
(en)
*
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
US5001139A
(en)
*
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
DE3802996A1
(de)
|
1988-02-02 |
1989-08-10 |
Cassella Ag |
Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen
|
|
US5424399A
(en)
*
|
1988-06-28 |
1995-06-13 |
The Children's Medical Center Corporation |
Human CR3α/β heterodimers
|
|
US5149780A
(en)
*
|
1988-10-03 |
1992-09-22 |
The Scripps Research Institute |
Peptides and antibodies that inhibit integrin-ligand binding
|
|
JPH06500555A
(ja)
*
|
1990-08-27 |
1994-01-20 |
カイロン コーポレイション |
病気の処置のためのペプチドの薬物
|
|
US5288854A
(en)
*
|
1990-11-28 |
1994-02-22 |
Center For Blood Research, Inc. |
Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
|
|
JP3679112B2
(ja)
*
|
1991-10-04 |
2005-08-03 |
アメリカ合衆国 |
細胞接着分子の遮断による眼の炎症の治療
|
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6162432A
(en)
*
|
1991-10-07 |
2000-12-19 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
DE69326829D1
(de)
*
|
1992-02-28 |
1999-11-25 |
Univ Texas |
Verwendung einer therapeutischen ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON VERBRENNUNGEN
|
|
US5298492A
(en)
*
|
1992-08-04 |
1994-03-29 |
Schering Corporation |
Diamino acid derivatives as antihypertensives
|
|
WO1994004188A1
(en)
*
|
1992-08-21 |
1994-03-03 |
Genentech, Inc. |
Method for treating an lfa-1-mediated disorder
|
|
US5397791A
(en)
*
|
1993-08-09 |
1995-03-14 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
ES2147210T3
(es)
*
|
1993-12-03 |
2000-09-01 |
Hoffmann La Roche |
Derivados de acido acetico como medicamentos.
|
|
US5470953A
(en)
*
|
1993-12-23 |
1995-11-28 |
Icos Corporation |
Human β2 integrin α subunit
|
|
US6228383B1
(en)
|
1994-03-03 |
2001-05-08 |
Gs Development Ab |
Use of fatty acid esters as bioadhesive substances
|
|
CA2188287A1
(en)
|
1994-04-19 |
1995-10-26 |
Stephen Benedict |
Icam-1/lfa-1 short-chain peptides and method of using same
|
|
US5585359A
(en)
*
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
EP0710657B1
(de)
*
|
1994-11-02 |
1998-08-26 |
MERCK PATENT GmbH |
Adhäsionsrezeptor-Antagonisten
|
|
US5747035A
(en)
*
|
1995-04-14 |
1998-05-05 |
Genentech, Inc. |
Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
|
|
JPH11510837A
(ja)
|
1995-07-28 |
1999-09-21 |
フォーカル，インコーポレイテッド |
薬物送達のための制御された放出薬剤および組織処置薬剤としての使用のためのマルチブロック生分解性ヒドロゲル
|
|
WO1998023608A1
(en)
*
|
1996-11-27 |
1998-06-04 |
Dupont Pharmaceuticals Company |
Novel integrin receptor antagonists
|
|
ES2306482T3
(es)
|
1997-08-28 |
2008-11-01 |
Novartis Ag |
Antagonistas de antigeno-1 funcion con funcion de linfocito.
|
|
US6541606B2
(en)
*
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
HUP0101587A3
(en)
|
1998-03-27 |
2003-03-28 |
Genentech Inc |
Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
|
|
US6331640B1
(en)
|
1998-10-13 |
2001-12-18 |
Hoffmann-La Roche Inc. |
Diaminopropionic acid derivatives
|
|
US6670321B1
(en)
*
|
1998-12-30 |
2003-12-30 |
The Children's Medical Center Corporation |
Prevention and treatment for retinal ischemia and edema
|
|
US6773916B1
(en)
*
|
1999-01-05 |
2004-08-10 |
The Flinders University Of South Australia |
Agents and methods for treatment and diagnosis of ocular disorders
|
|
EP1028114A1
(en)
*
|
1999-02-13 |
2000-08-16 |
Aventis Pharma Deutschland GmbH |
Novel guanidine derivatives as inhibitors of cell adhesion
|
|
US6605597B1
(en)
*
|
1999-12-03 |
2003-08-12 |
Cv Therapeutics, Inc. |
Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
|
|
US6294522B1
(en)
*
|
1999-12-03 |
2001-09-25 |
Cv Therapeutics, Inc. |
N6 heterocyclic 8-modified adenosine derivatives
|
|
DE60039783D1
(de)
*
|
1999-12-14 |
2008-09-18 |
Genentech Inc |
Lfa-1 antagonisten und tnf-alpha antagonisten zur
|
|
AU777721B2
(en)
|
2000-01-14 |
2004-10-28 |
Larson, Richard |
Peptide inhibitors of LFA-1/ICAM-1 interaction
|
|
US6515124B2
(en)
|
2000-02-09 |
2003-02-04 |
Hoffman-La Roche Inc. |
Dehydroamino acids
|
|
EP1296943A1
(fr)
*
|
2000-05-05 |
2003-04-02 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) |
Derives d'aminoacides et leur application a titre de medicaments
|
|
NZ523445A
(en)
*
|
2000-06-29 |
2004-10-29 |
Abbott Lab |
Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
|
|
AR030817A1
(es)
*
|
2000-10-02 |
2003-09-03 |
Novartis Ag |
Derivados de diazacicloalcanodiona
|
|
US6653478B2
(en)
*
|
2000-10-27 |
2003-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
|
|
GB0028367D0
(en)
*
|
2000-11-21 |
2001-01-03 |
Celltech Chiroscience Ltd |
Chemical compounds
|
|
AU2002248142B2
(en)
|
2000-11-28 |
2007-11-01 |
Genentech, Inc. |
LFA-1 antagonist compounds
|
|
DE60216830T2
(de)
*
|
2001-02-06 |
2007-06-14 |
Pfizer Products Inc., Groton |
Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
|
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
|
US6391290B1
(en)
|
2001-03-21 |
2002-05-21 |
Schering-Plough Healthcare Products, Inc. |
Skin care compositions
|
|
US6872382B1
(en)
*
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
JP4583751B2
(ja)
*
|
2001-06-06 |
2010-11-17 |
アベンティス・フアーマ・リミテッド |
炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
|
|
CA2454618C
(en)
*
|
2001-07-24 |
2012-04-03 |
Biogen Idec Ma, Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
|
RU26988U1
(ru)
|
2002-05-06 |
2003-01-10 |
Закрытое акционерное общество "ДУКС-ЛИЗИНГ" |
Кондуктор для сверления отверстий
|
|
WO2003103587A2
(en)
*
|
2002-06-06 |
2003-12-18 |
Dana-Farber Cancer Institute |
Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
|
|
US7785578B2
(en)
*
|
2002-10-11 |
2010-08-31 |
Aciont, Inc. |
Non-invasive ocular drug delivery
|
|
CN1902195B
(zh)
*
|
2003-11-05 |
2016-03-23 |
萨可德生物科学公司 |
细胞粘着调节剂
|
|
AU2004287875B2
(en)
*
|
2003-11-05 |
2011-06-02 |
Bausch + Lomb Ireland Limited |
Modulators of cellular adhesion
|
|
WO2005065668A2
(en)
*
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
AU2005254980A1
(en)
*
|
2004-06-09 |
2005-12-29 |
Genentech, Inc. |
Method of treating granuloma annulare or sarcoid
|
|
MX2007000851A
(es)
*
|
2004-07-22 |
2007-03-26 |
Wyeth Corp |
Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
|
|
DK2444079T3
(en)
*
|
2005-05-17 |
2017-01-30 |
Sarcode Bioscience Inc |
Compositions and Methods for the Treatment of Eye Diseases
|
|
ES2630406T3
(es)
*
|
2007-10-19 |
2017-08-21 |
Sarcode Bioscience Inc. |
Composición y procedimientos para el tratamiento de la retinopatía diabética
|
|
EP2265124A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
|
|
US8080562B2
(en)
*
|
2008-04-15 |
2011-12-20 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
EP2276508A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
|
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
CA2879982C
(en)
*
|
2012-07-25 |
2020-09-01 |
Sarcode Bioscience Inc. |
Lfa-1 inhibitor and polymorph thereof
|